The oviduct and ovarian cancer: Causality, clinical implications, and "targeted prevention"

Clinical Obstetrics and Gynecology

Volumn 55, Issue 1, 2012, Pages 24-35

  Crum, Christopher P ^a,b   McKeon, Frank D ^a,b   Xian, Wa ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

BRCA; fimbria; ovarian cancer; p53; precancer; serous cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CARCINOGENICITY; GENE FUNCTION; GENE MUTATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; OVARY CANCER; OVIDUCT; SALPINGOOOPHORECTOMY; SEROLOGY; UTERINE TUBE;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; EARLY DIAGNOSIS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857551527     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31824b1725     Document Type: Article

References (52)

1. American Cancer Society. Cancer facts and figures 2007.www.cancer.org.
2. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007; 107:159-162. (Pubitemid 47575743)
3. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518. (Pubitemid 38529752)
4. Helm CW, Edwards RP. Malignant lesions of the ovary. 2008 April. http://www.emedicine.com/med/topic3306.htm.
5. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009;3:165-170.
6. Gershenson DM, Tortolero-Luna G, Malpica A, et al. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am. 1996;23:475-543. (Pubitemid 26185972)
7. Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol. 1989;35:236-239. (Pubitemid 19268565)
8. Stewart SL, Wike JM, Foster SL, et al. The incidence of primary fallopian tube cancer in the United StatesGynecol Oncol. 2007;107:392-397. (Pubitemid 350160878)
9. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germ line mutation status. Am J Surg Pathol. 2001;25:1283-1289. (Pubitemid 32917122)
10. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56. (Pubitemid 36027101)
11. Powell CB, Kenley E, Chen LM, et al. Risk reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23: 127-132. (Pubitemid 41702631)
12. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64. (Pubitemid 41815050)
13. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990. (Pubitemid 47477278)
14. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9. (Pubitemid 351627965)
15. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169. (Pubitemid 46175016)
16. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165.
17. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-417.
18. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-1416.
19. Leonhardt K, Einenkel J, Sohr S, et al. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011;30:417-424.
20. Roh MH, Yassin Y, Miron A, et al. High-grade fimbrial-ovarian carcinomas are unified by alteres p53, PTEN and PAX2 expression. Mod Pathol. 2010;23: 1316-1324.
21. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
22. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456. (Pubitemid 33069670)
23. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35. (Pubitemid 46092026)
24. Hutson R, Ramsdale J, Wells M. P53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology. 1995;27:367-371.
25. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000;89:383-390. (Pubitemid 30489888)
26. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008;109:168-173.
27. Cass I, Holschneider C, Datta N, et al. BRCA-mutation associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-1334. (Pubitemid 41668953)
28. Saleemuddin A, Folkins AK, Garrett L, et al. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol. 2008;111:226-232.
29. Vicus D, Shaw PA, Finch A, et al. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecol Oncol. 2010;118:295-298.
30. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010; 29:1103-1113.
31. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:90-100. Review.
32. Ito R, Kondo F, Yamaguchi T, et al. Pancreatic intraepithelial neoplasms in the normal appearing pancreas: on their precise relationship with age. Hepatogastroenterology. 2008;55:1103-1106. (Pubitemid 351975995)
33. Epstein JI. Precursor lesions to prostatic adenocarcinoma. Virchows Arch. 2009; 454:1-16.
34. Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010;116:5261-5271.
35. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22: 1133-1138.
36. Mehra K, Mehrad M, Ning G, et al. SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011;3:625-634.
37. Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube. J Pathol. 2010;222:110-116.
38. Laury AR, Ning G, Quick CM, et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol. 2011;35:1759-1765.
39. Quick CM, Ning G, Bijron J, et al. PAX2- null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Mod Pathol. 2012. (in press).
40. Medeiros F,Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236. (Pubitemid 43740193)
41. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies fromwomenwith BRCAmutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009;33:1878-1885.
42. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009;22: 985-988.
43. Kwon JS, Daniels MS, Sun CC, et al. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010;28:675-682.
44. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346:1609-1615. (Pubitemid 34755668)
45. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192.
46. Piek JM, Torrenga B, Hermsen B, et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2003;2:73-78. (Pubitemid 37247978)
47. Domchek SM, Gaudet MM, Stopfer JE, et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat. 2010;119:409-414.
48. Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. AdvAnat Pathol. 2010;17:293-302. Review.
49. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 2010;220:392-400.
50. Soslow RA, Han G, Park KJ, Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012. (In press).
51. McAlpine JN, El Hallani S, Lam SF, et al. Auto fluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol. 2011;120: 385-392.
52. Dietl J, Wischhusen J, Häusler SF. The post-reproductive fallopian tube: better removed? Hum Reprod. 2011;26: 2918-2924.